Literature DB >> 9203850

Pharmacokinetic considerations in the development of peptide-based imaging agents.

J Lister-James1, B R Moyer, R T Dean.   

Abstract

Pharmacokinetic factors to be considered in the development of peptide-based imaging agents are reviewed. These include size, plasma protein binding, lipophilicity, resistance or susceptibility to proteolysis and radiolabel integrity. These factors are discussed in the context of several examples of thrombus and tumor imaging agents either commercially available or in development.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9203850

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN： 1125-0135


  4 in total

1.  In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  J Labelled Comp Radiopharm       Date:  2009-12-01       Impact factor: 1.921

2.  Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.

Authors:  Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever
Journal:  Bioconjug Chem       Date:  2008-09-23       Impact factor: 4.774

3.  (99m)Tc-NC100668, a new tracer for imaging venous thromboemboli: pre-clinical biodistribution and incorporation into plasma clots in vivo and in vitro.

Authors:  David Edwards; Joanne Lewis; Mark Battle; Rochelle Lear; Gill Farrar; D Jon Barnett; Vanessa Godden; Alexandra Oliveira; Catherine Coombes; Håkan Ahlström
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-28       Impact factor: 9.236

Review 4.  pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents.

Authors:  Oleg A Andreev; Donald M Engelman; Yana K Reshetnyak
Journal:  Mol Membr Biol       Date:  2010-10-13       Impact factor: 2.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.